1. Meakins JL, Solomkin JS, Allo MD et al. A proposed classification of intra-abdominal
infections: stratification of etiology and risk for future therapeutic trials. Arch
Surg 1984; 119: 1372–8.
2. Solomkin JS, Mazuski JE, Baron EJ et al. Guidelines for the Selection of Anti-infective
Agents for Complicated Intra-abdominal Infections. Clin Infect Dis 2003; 37:
997–1005.
3. Finegold SM. Abdominal and perineal infections. In: Finegold SM, ed. Anaerobic
bacteria in human disease. New York: Academic Press; 1977; 257–313.
4. Gorbach SL, Thadepalli H, Norsen J et al. Anaerobic microorganisms in intraabdominal
infections. In: Balows A, de Haan RM, Dowell VR et al., eds. Anaerobic
bacteria: role in disease. Springfield, IL: Charles C Thomas; 1974; 399–407.
5. Altemeier WA. The bacterial flora of acute perforated appendicitis with peritonitis.
Ann Surg 1938; 107: 517–28.
6. Swenson RM, Lorber B, Michaelson TC et al. The bacteriology of intra-abdominal
infections. Arch Surg 1974; 109: 389–98.
7. Bennion RS, Thompson JL, Baron EL et al. Gangrenous and perforated appendicitis
with peritonitis: treatment and bacteriology. Clin Ther 1990; 12 (Suppl. C): 31–44.
8. Mazuski JE, Sawyer RG, Nathens AB et al. The Surgical Infection Society guidelines
on antimicrobial therapy for intra-abdominal infections: an executive summary.
Surg Infections 2002; 3 (3): 161–73.
9. Soussy CJ, Nguyen J, Goldstein F et al. In vitro antibacterial activity of moxifloxacin
against hospital isolates: a multicentre study. Clin Microbiol Infect 2003; 9
(10): 997–1005.
10. Ambler JE, Choudhri SH, Haverstock D et al. Moxifloxacin in vitro activity
against non-pneumococcal streptococci isolated from six recent clinical studies
{abstr #P1301]. 16th European Congress of Clinical Microbiology Infectious Diseases,
April 1–4, 2006. Nice, France.
11. Edmistone CE, Krepel JK, Seabrook GR et al. In Vitro Activities of Moxifloxacin
against 900 Aerobic and Anaerobic Surgical Isolates from Patients with Intra-
Abdominal and Diabetic Foot Infections. Antimicrob Agents Chemother 2004; 48: 1012–6.
12. Thadepalli H, Chuah SK, Gollapudi S. Therapeutic efficacy of moxifloxacin, a
new quinolone, in the treatment of experimental intra-abdominal abscesses
induced by Bacteroides fragilis in mice. Chemotherapy 2004; 50 (2): 76–80.
13. Hermsen ED, Hovde LB, Sprandel KA et al. Moxifloxacin Monotherapy against a
Mixed Infection of Escherichia coli and Bacteroides fragilis in an In Vitro Pharmacodynamic
Model. Antimicrob Agents Chemother 2005; 49: 685–9.
14. Schaumann R, Blatz R, Beer J et al. Effect of moxifloxacin versus imipenem/cilastatin
treatment on the mortality of mice infected intravenously with different strains
of Bacteroides fragilis and Escherichia coli. J Antimicrob Chemother 2004; 53 (2):
318–24.
15. Stass H, Rink AD, Delesen H et al. Pharmacokinetics of moxifloxacin in tissues of the
CI-tract [Abstr #O359]. 16th European Congress of Clinical Microbiology Infectious Diseases, April 1–4, 2006. Nice, France.
16. Stass H, Rink AD, Delesen H et al. Pharmacokinetics and peritoneal penetration
of moxifloxacin in peritonitis. J Antimicrob Chemother 2006; 58: 693–6.
17. Schwab D, Grauer M, Hahn EG, Muhldorfer S. Biliary secretion of moxifloxacin
in obstructive cholangitis and the non-obstructed biliary tract. Aliment Pharmacol
Ther 2005; 22 (5): 417–22.
18. Barth J, Jager D, Mundkowski R et al. Single- and multiple-dose pharmacokinetics
of intravenous moxifloxacin in patients with severe hepatic impairment. J
Antimicrob Chemother 2008; 62 (3): 575–8.
19. Rink AD, Stass H, Delesen H et al. Pharmacokinetics and tissue penetration of
moxifloxacin in intervention therapy for intra-abdominal abscess. Clin Drug Investig
2008; 28 (2): 71–9.
20. Malangoni M, Song J, Choudhri S et al. Sequential IV/PO moxifloxacin versus
IN piperacillin/tazobactam ± PO amoxicillin/clavulanate for treatment of complicated
intra-abdominal infections [Abstr #402710]. 44th Interscience Conf
Antimicrob Agents Chemother, Oct 30 – Nov 2, 2004. Washington, DC.